Misplaced Pages

DOV Pharmaceutical: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 19:20, 2 November 2007 editSubdolous (talk | contribs)1,332 edits Nominated for deletion: see Misplaced Pages:Articles for deletion/DOV_Pharmaceutical← Previous edit Revision as of 18:14, 5 November 2007 edit undoA. B. (talk | contribs)Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers51,784 edits add 7 references from reliable sources + company web site + Template:Finance linksNext edit →
Line 5: Line 5:


'''DOV Pharmaceutical''', a ] company, focuses on therapies primarily for central nervous system conditions. The firm's lead drug candidate, ], is said to treat ]. Indiplon targets the same subset of neurotransmitter receptors affected by ] and ], but with more specificity to avoid the side effects associated with those drugs. DOV Pharmaceutical, ], and ] are working on the candidate. Other candidates in DOV's pipeline target ] and ], ], ], ], and other disorders. '''DOV Pharmaceutical''', a ] company, focuses on therapies primarily for central nervous system conditions. The firm's lead drug candidate, ], is said to treat ]. Indiplon targets the same subset of neurotransmitter receptors affected by ] and ], but with more specificity to avoid the side effects associated with those drugs. DOV Pharmaceutical, ], and ] are working on the candidate. Other candidates in DOV's pipeline target ] and ], ], ], ], and other disorders.

==References==
*Hess, Diane, , ], 1 May 2002. Retrieved 5 November 2007.
*Simpson, Stephen D. , ], 26 April 2006. Retrieved 5 November 2007.
*Krauskopf, Lewis, , ], 2 May 2002. Retrieved 5 November 2007.
*Lynn, Kathleen, , ], 11 October 2006. Retrieved 5 November 2007.
*Maeillo, Michael, , ], 2 September 2002. Retrieved 5 November 2007.
*, ], 25 April, 2002. Retrieved 5 November 2007.
*, ] profile. Retrieved 5 November 2007.

==External links==

{{Finance links
| name = DOV Pharmaceutical Inc.
| symbol = DOVP
| sec_cik = 0001066833
| hoovers = 10425
}}


] ]

Revision as of 18:14, 5 November 2007

An editor has nominated this article for deletion.
You are welcome to participate in the deletion discussion, which will decide whether or not to retain it.Feel free to improve the article, but do not remove this notice before the discussion is closed. For more information, see the guide to deletion.
Find sources: "DOV Pharmaceutical" – news · newspapers · books · scholar · JSTOR%5B%5BWikipedia%3AArticles+for+deletion%2FDOV+Pharmaceutical%5D%5DAFD


DOV Pharmaceutical, a biotechnology company, focuses on therapies primarily for central nervous system conditions. The firm's lead drug candidate, Indiplon, is said to treat insomnia. Indiplon targets the same subset of neurotransmitter receptors affected by Valium and Xanax, but with more specificity to avoid the side effects associated with those drugs. DOV Pharmaceutical, Neurocrine Biosciences, and Pfizer are working on the candidate. Other candidates in DOV's pipeline target depression and angina, pain, anxiety, high blood pressure, and other disorders.

References

External links

Company web site

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it.

Categories: